In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia
- PMID: 3771801
- PMCID: PMC423848
- DOI: 10.1172/JCI112729
In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia
Abstract
The causes of primary moderate hypercholesterolemia are not understood, but some patients have reduced fractional clearance rates (FCRs) for low density lipoproteins (LDL). This could be due to either decreased activity of LDL receptors or to a defect in structure (or composition) of LDL that reduces its affinity for receptors. To distinguish between these causes, simultaneous turnover rates of autologous and normal homologous LDL were determined in 15 patients with primary moderate hypercholesterolemia. In 10, turnover rates of both types of LDL were indistinguishable, which indicated that autologous LDL was cleared as efficiently as normal homologous LDL. In five others, FCRs for autologous LDL were significantly lower than for homologous LDL. Two of the latter five were treated with mevinolin, and although FCRs for both types of LDL rose during treatment, differences in FCRs between the two types of LDL persisted. In these five patients, autologous LDL appeared to be a poor ligand for LDL receptors.
Similar articles
-
Coinheritance of two mild defects in low density lipoprotein receptor function produces severe hypercholesterolemia.J Clin Endocrinol Metab. 1991 Jan;72(1):179-87. doi: 10.1210/jcem-72-1-179. J Clin Endocrinol Metab. 1991. PMID: 1986017
-
[Catabolism of low-density lipoproteins via receptors and its regulation].Ann Biol Clin (Paris). 1986;44(5):545-50. Ann Biol Clin (Paris). 1986. PMID: 3544977 Review. French.
-
Metabolic basis of primary hypercholesterolemia.Circulation. 1991 Jul;84(1):118-28. doi: 10.1161/01.cir.84.1.118. Circulation. 1991. PMID: 2060088
-
Changes in ultracentrifugally separated plasma lipoprotein subfractions in patients with polygenic hypercholesterolemia, familial combined hyperlipoproteinemia, and familial hypercholesterolemia after treatment with atorvastatin.J Clin Lipidol. 2015 Mar-Apr;9(2):210-6. doi: 10.1016/j.jacl.2014.12.007. Epub 2014 Dec 16. J Clin Lipidol. 2015. PMID: 25911077
-
Mechanisms of primary hypercholesterolemia in humans.Am Heart J. 1987 Feb;113(2 Pt 2):493-502. doi: 10.1016/0002-8703(87)90620-x. Am Heart J. 1987. PMID: 3544763 Review.
Cited by
-
The genetic basis of familial hypercholesterolemia: inheritance, linkage, and mutations.Appl Clin Genet. 2010 Aug 5;3:53-64. doi: 10.2147/tacg.s8285. Print 2010. Appl Clin Genet. 2010. PMID: 23776352 Free PMC article.
-
Development of complex atherosclerotic lesions in pigs with inherited hyper-LDL cholesterolemia bearing mutant alleles for apolipoprotein B.Am J Pathol. 1991 Jul;139(1):139-47. Am J Pathol. 1991. PMID: 1853929 Free PMC article.
-
Apolipoprotein B amino acid 3611 substitution from arginine to glutamine creates the Ag (h/i) epitope: the polymorphism is not associated with differences in serum cholesterol and apolipoprotein B levels.Hum Genet. 1989 Jul;82(4):322-6. doi: 10.1007/BF00273990. Hum Genet. 1989. PMID: 2472350
-
Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals.J Hum Genet. 2018 Feb;63(2):213-230. doi: 10.1038/s10038-017-0347-1. Epub 2017 Dec 1. J Hum Genet. 2018. PMID: 29192238 Clinical Trial.
-
Familial defective apolipoprotein B-100: a common cause of primary hypercholesterolemia.Clin Investig. 1992 Jan;70(1):77-84. doi: 10.1007/BF00422946. Clin Investig. 1992. PMID: 1600334 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical